Glaukos (GKOS) Investor presentation summary

Innovation and market leadership

• Focuses on pioneering solutions for chronic eye diseases, leveraging a hybrid pharmaceutical-device model to address large and underserved populations.

• Invested over $800 million in R&D since 2018, supporting a robust pipeline with 13 disclosed programs and 12 commercialized products.

• Recognized as a new market pioneer, building durable markets and advancing standards of care.

Interventional glaucoma advancements

• Introduced iDose TR, a long-duration, FDA-approved intracameral implant for glaucoma, designed to address patient non-compliance and deliver up to 3 years of therapy.

• Expanding the iDose platform with next-generation products (TRIO, TREX) to extend duration and facilitate in-office administration, with positive early clinical results.

• iStent infinite, a best-in-class MIGS therapy, provides up to 240° of outflow coverage and is supported by 14 years of commercial leadership and 300+ publications.

• Product roadmap includes multiple FDA-approved and late-stage pipeline products targeting various glaucoma severities.

Interventional keratoconus innovation

• Epioxa, the first FDA-approved epithelium-on therapy for keratoconus, offers a streamlined, incision-free procedure with faster recovery and is now commercially available.

• Less than 20% of newly diagnosed progressive keratoconus eyes currently access approved therapy, highlighting significant unmet need.

• Pipeline includes a third-generation iLink therapy using biomechanical modeling for customized treatment, currently in Phase 2 trials.